Atrosab 

Atrosab is a humanized IgG1 antagonistic anti-TNFR1 antibody. Atrosab inhibits TNF-mediated Apoptosis induction and IL-6 and IL-8 production. Atrosab reduces neurological deficits. Atrosab can be used for research of inflammatory disease. The recommend isotype control is Human IgG1 kappa, Isotype Control (HY-P99001)^[1][2][3].

Atrosab (0.1-1000 nM, preincubate with antibody for 1 h, then add the stimulant TNF and co-incubate for 7 hours) inhibits in a dose-dependent manner the TNF-induced apoptosis of Kym-1 cells ^[1].
Atrosab (0.1-1000 nM, preincubate with antibody for 1 h, then add the stimulant TNF and co-incubate for 7 hours) inhibits release of IL-6 from HeLa cells and IL-8 from HT1080 cells induced by TNF dose-dependently^[1].
Atrosab (100 μg/mL,24 h) reduces endothelial cell expression of adhesion molecules and T cell adhesion^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Atrosab (i.v., twice weekly, 28 days) has been shown to be effective for inflammatory diseases such as rheumatoid arthritis (RA) and multiple sclerosis (MS) in both monkeys and human TNF transgenic/human TNFR1 knock-in mice model and in human TNFR1 knock-in mice (hp55K/i) EAE model ^[2].
Atrosab (20 mg/kg, i.p.) reduces immune cell infiltrates in humanized TNFR1 knock-in mice ^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1365659-05-7

Liquid

Colorless to light yellow

[Atrosab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Immobilized Human TNFR1,His Tag can bind Atrosab. The EC₅₀ for this effect is 8.161 ng/mL.
• 
  Loaded Atrosab on AHC2 biosensor, can bind TNFRSF1A Protein, Human (His, HY-P70801) with an affinity constant of 1.151E-08 M as determined in BLI assay.

• [1]. Zettlitz KA, et al. ATROSAB, a humanized antagonistic anti-tumor necrosis factor receptor one-specific antibody. MAbs. 2010 Nov-Dec;2(6):639-47.  [Content Brief]

  [2]. Zettlitz KA, et al. ATROSAB, a humanized antagonistic anti-tumor necrosis factor receptor one-specific antibody.  [Content Brief]

  [3]. E. Guenzi, et al. FRI0231 Atrosab, a humanized antibody directed against tnf-receptor 1, hold great promises for the treatment of rheumatoid arthritis. Ann Rheum Dis. 2013 Jun 14; 72(3):A451.

  [4]. Williams SK, et al. Anti-TNFR1 targeting in humanized mice ameliorates disease in a model of multiple sclerosis. Sci Rep. 2018 Sep 11;8(1):13628.  [Content Brief]